Rucaparib (AG-014699) phosphate

For research use only. Not for use in humans.

製品コードS1098 別名：PF-01367338

CAS No. 459868-92-9

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with K_i of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

サイズ

価格(税別)

在庫

10mM (1mL in DMSO)	JPY 24200	あり
5mg	JPY 21900	あり
10mg	JPY 36800	あり
50mg	JPY 113200	あり

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297 | 電子メール：[email protected]

文献中Selleckの製品使用例(86)

製品安全説明書

PARP阻害剤の選択性比較

生物活性

製品説明

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with K_i of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

特性

The first PARP inhibitor used in clinical trials combined with temozolomide.

ターゲット

PARP ^[1]
(Cell-free assay)

1.4 nM(Ki)

体外試験

Rucaparib is a potent inhibitor of purified full-length human PARP-1 and shows higher inhibition of cellular PARP in LoVo and SW620 cells. Besides, Rucaparib binds detectably to eight other PARP domains, including PARP2, 3, 4, 10, 15, 16, TNKS1 and TNKS2. ^[1] ^[2] The radio-sensitization by Rucaparib is due to downstream inhibition of activation of NF-κB, and is independent of SSB repair inhibition. Rucaparib could target NF-κB activated by DNA damage and overcome toxicity observed with classical NF-κB inhibitors without compromising other vital inflammatory functions. ^[3] Rucaparib inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilised D283Med cells. ^[4]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
BT-474	M3zsbmZ2dmO2aX;uJGF{e2G7	M2rueFAvOS9zL{WwNE8yODByIH7N			M3ixdolvcGmkaYTzJHBCWlBiYXP0bZZqfHliYYSgd5RienSrbnegZ49v[2W{boTyZZRqd25ib3[gOVAxKG6P	MkixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMki0OVUoRjJ3MUK4OFU2RC:jPh?=
BT474	M3vRUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTkT4pZPTByIH7N	MY[xNQKBmzF3wrDk		MkX0doVlfWOnczDj[YxtKGe{b4f0bEBqdiC2aHWg[o92eiCuaX7ld{BidmRic3nncolncWOjboTsfS=>	NX3r[\|VVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlg1PTVpPkK1NVI5PDV3PD;hQi=>
SKBR3	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVq0dnc6PTByIH7N	NX;DSmlrOTEkgKOxOeKh\A>?		MofmdoVlfWOnczDj[YxtKGe{b4f0bEBqdiC2aHWg[o92eiCuaX7ld{BidmRic3nncolncWOjboTsfS=>	MnX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMki0OVUoRjJ3MUK4OFU2RC:jPh?=
AU565	MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTae\|JpPTByIH7N	MUOxNQKBmzF3wrDk		M3jBUpJm\HWlZYOgZ4VtdCCpcn;3eIghcW5idHjlJIZwfXJibHnu[ZMh[W6mIIPp[45q\mmlYX70cJk>	M{\USVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK4OFU2Lz5{NUGyPFQ2PTxxYU6=
EFM192A	MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLUOVAxKG6P	NF;DV2MyOOLCk{G1xsBl		NFHG[I5z\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIITo[UBnd3W{IHzpcoV{KGGwZDDzbYdvcW[rY3HueIx6	NXHCNGhWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlg1PTVpPkK1NVI5PDV3PD;hQi=>
MDA-MB-231	MWPGeY5kfGmxbjDBd5NigQ>?	MlXYNVAwOjBxNECg{txO	MomwNlQhcA>?		MorvbY5kemWjc3XzJJAuSUuWIHzleoVteyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NIf2dWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyNFE2Oid-MkS0NlAyPTJ:L3G+
MDA-MB-231	M3v3VGNmdGxiVnnhZoltcXS7IFHzd4F6	NGLnTI8xNjFvNECg{txO	MnvHNlQhcA>?		Mof5TWM2OOLCiU5ihKkyPy55N9Mg{txO	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{MEG1Nkc,OjR2MkCxOVI9N2F-
MDA-MB-231	MX7BdI9xfG:\|aYOgRZN{[Xl?	NVe1WZdKOTBxMkCvOFAh\|ryP	M4jyVFI1KGh?		NX\zSm01cW6mdXPld{BieG:ydH;zbZMh\G:\|ZTDk[ZBmdmSnboTsfS=>	Mkj5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkCxOVIoRjJ2NEKwNVUzRC:jPh?=
MDA-MB-231	M1XFfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fsWVExNzJyL{SwJO69VQ>?	MoPpNlQhcA>?		NWrTWHht[myxY3vzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25iaX6gS\|IwVSCyaHHz[S=>	M37GNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKwNVUzLz5{NESyNFE2OjxxYU6=
H460	NFfzfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjnbIE4PDByIH7N	NIfsW5kzPMLiaB?=		NXnzN5dNcW6lcnXhd4V{KGOnbHz1cIFzKHKjZHnvd4Vve2m2aY\peJk>	NXjENIUzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NVE3OTFpPkK0OFEyPjFzPD;hQi=>
A549	NUjzd3BJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HhVVQxOCCwTR?=	Mn3MNlTDqGh?		NFvoUHVqdmO{ZXHz[ZMh[2WubIXsZZIhemGmaX;z[Y5{cXSrdnn0fS=>	NV3kbG1YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NVE3OTFpPkK0OFEyPjFzPD;hQi=>
DT40	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2DSU2lEPTB;MkGgcm0>	Mom1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|NU[4NVMoRjJ2M{W2PFE{RC:jPh?=
DU145	M3jFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLuNItKSzVyPUG4JI5O	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3NkixN{c,OjR\|NU[4NVM9N2F-
COLO704	M4LXfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTJwNUKgxtEhOC54NzFOwG0>	M4\0PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OVMANAb	NI\tNndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1KxSGlEPTB;Mj61PEDDuSByLkO4JO69VQ>?	MlTtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
OV177	NYK5SZA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTxVoNKSzVyPUKuO\|ghyrFiMD63NUDPxE1?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OAW28	M2raeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTzRXFQUUN3ME2zMlYyKMLzIECuNlgh\|ryP	M{XrO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OVSAHO	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTNwNkSgxtEhOC5\|MzFOwG0>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OVKATE	NUPNcnd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4S4eWlEPTB;Mz62OEDDuSBzLke5JO69VQ>?	M3HJZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OVCAR3	MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mkf0TWM2OD1\|Lke0JOKyKDBwNECg{txO	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
PEO14	NXjrSIFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7EWlRxUUN3ME2zMlg1KMLzIECuO\|Yh\|ryP	MlvHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
A2780	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\KTWM2OD1\|Lkm0JOKyKDBwMkWg{txO	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OVTOKO	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLoTWM2OD12LkG0JOKyKDFwNUOg{txO	NFjGbXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
KURAMOCHIb	NW\odII3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjBe\|RYUUN3ME20MlM1KMLzIECuNlkh\|ryP	NXfMXIg5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
TOV21G	NV;TZ\|NlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVv4fppQUUN3ME21MlA4KMLzIEGuN\|Ah\|ryP	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OVISE	NYjNd4VTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{G4d2lEPTB;NT62PEDDuSByLkKzJO69VQ>?	NXnESJBLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
KK	MkTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTZwMUWgxtEhOS52MjFOwG0>	M33ZPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
RMUGS	NUnNcmFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTdwMEOgxtEhOS56MzFOwG0>	MlvZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
PEO6	M17CZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTdwME[gxtEhOC55NDFOwG0>	NVr3eIkyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
OVCA429	MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTaWWFCUUN3ME24MlI6KMLzIEGuOlQh\|ryP	NV3ET4pQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
OV167	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHGyXGpKSzVyPUiuN\|MhyrFiMT6xPEDPxE1?	NF6wSXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
RMG1	NXzwS3I{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUn6ToZyUUN3ME25MlMzKMLzIEKuN\|Yh\|ryP	M1vOTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OVCAR5	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfDcpNKSzVyPUmuOVAhyrFiMj61PUDPxE1?	NELTc209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
EFO21	MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfCTWM2OD17LkmyJOKyKDFwOEeg{txO	MnjUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
ES2	NF;FWmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTFyLkGyJOKyKDFwMkOg{txO	NVmyfIdkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
Tyk-nu	MkHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTQ[ZJqUUN3ME2xNE4zOCEEsTCxMlEzKM7:TR?=	M1TVRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
CAOV3	M{nwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWGyTVJDUUN3ME2xNE4{PyEEsTCwMlg4KM7:TR?=	NF;zdZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OV207	NIDWN5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTF{LkK3JOKyKDBwM{Kg{txO	NVj5eWRXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
HEY	NVfhR\|VpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13CTWlEPTB;MUOuNFEhyrFiMD63OUDPxE1?	NELTb5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
DOV13	M2rNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX2xWnJGUUN3ME6xOUDPxE1?	NGro[\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
EFO27	NEG0VFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrx[Fd4UUN3ME6xOUDPxE1?	MkDqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
HEY C2	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXsSoZLUUN3ME6xOUDPxE1?	MmD6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
KOC-7cc	NYHMdpZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRjF3IN88US=>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
MCASb	MlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1T2[2lEPTB-MUWg{txO	M4K0WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OAW42	MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\UTWM2OD5zNTFOwG0>	M{nWN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OV2008	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHWTWM2OD5zNTFOwG0>	NWf5WZVkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
OV90	NH7GXXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3P6TWlEPTB-MUWg{txO	NYfhRplyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
OVCA420b	MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRjF3IN88US=>	NU\u[pdxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
OVCA432	NWnBW3ljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRjF3IN88US=>	NGLDU2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
PEA2	NEn6[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTmVXBtUUN3ME6xOUDPxE1?	NIDIUlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
SKOV3	NX7PTYx2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLVTWM2OD5zNTFOwG0>	M4fqVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
TOV112D	NH\xU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXicWoxNTNizszN			MXLJR\|UxRjF3IN88US=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
C4-2	MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYSwMVMh\|ryP	NWHpZZB4OTRiZB?=	MVfEUXNQ	MXjk[YNz\WG\|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6	NGPGUI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W2OVI1PCd-MkO1OlUzPDR:L3G+
PC3	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfrXWF{OC1\|IN88US=>	MoS2NVQh\A>?	NHfvR3hFVVOR	Mknj[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>?	Ml;PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkWyOFQoRjJ\|NU[1NlQ1RC:jPh?=
DU145	NILJ[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV2wMVMh\|ryP	M1HmV\|E1KGR?	NGjxV4hFVVOR	Ml\J[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>?	M4\zXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[1NlQ1Lz5{M{W2OVI1PDxxYU6=
VCaP	NWnCe2hST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUSwMVMh\|ryP	M3XjdFE1KGR?	Mn7xSG1UVw>?	MYfk[YNz\WG\|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6	M4LSU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[1NlQ1Lz5{M{W2OVI1PDxxYU6=
LNCaP	Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HtWFAuOyEQvF2=	NV73TZVMOTRiZB?=	NVXnSmFsTE2VTx?=	NH3ucVll\WO{ZXHz[ZMh[2:ub375JI52dWKncjDkc5NmKGSncHXu[IVvfGy7	NIH6OIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W2OVI1PCd-MkO1OlUzPDR:L3G+
MDA-MB-468	MoSwR4VtdCCYaXHibYxqfHliQYPzZZk>				NIDmXVlKSzVyPUmuO{DPxE1?	NXHIeY9[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2O\|gyPjFpPkKyOlc5OTZzPD;hQi=>
MDA-MB-231	NHPwOoxE\WyuIG\pZYJqdGm2eTDBd5NigQ>?				NGi1RYdKSzVyPUGzJO69VQ>?	MojSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4N{ixOlEoRjJ{Nke4NVYyRC:jPh?=
Cal-51	MWPD[YxtKF[rYXLpcIl1gSCDc4PhfS=>				NHLTSFBKSzVyPUiuOkDPxE1?	MnjJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4N{ixOlEoRjJ{Nke4NVYyRC:jPh?=
LoVo	NE\3[m9HfW6ldHnvckBie3OjeR?=		NIC0SYg{OCCvaX7z		NVv5VVhLUW6qaXLpeIlwdiCxZjDQRXJRKGmwIHj1cYFvKEyxVn:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyb3z5LGFFWClvcnnic5NmKHCxbInt[ZJqgmG2aX;uJIZweiB\|MDDtbY5{KGK7IH\seY9z\XOlZX7j[UBie3OjeTygSWM2OCB;IECuNFA1PjlizszNMi=>	NGj6[os9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
MX1	NHS3cI9EgXSxdH;4bYNqfHliYYPzZZk>				M1HrS2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KEKUQ1GxMYRm\mmlaXXueEBpfW2jbjDNXFEh[2WubIOsJGVEPTBiPTCwMlAxPTNizszNMi=>	M1TCc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO\|E4Lz5{Nk[1NlcyPzxxYU6=
Rosetta2 (DE3)	MnXpSpVv[3Srb36gZZN{[Xl?				M2mz[GlvcGmkaYTpc44hd2ZiaIXtZY4hVi22ZYLtbY5idCB4eHjpd{11[WepZXSgRXJVTDZiKEi3N{B1dyBzMU[xLUBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCUb4PleJRiOiBqRFWzLUBk\WyuczD1d4lv\yCQQVSrJIF{KHO3YoP0doF1\SCkeTDmcJVwemW\|Y3XuZ4Uh[XO\|YYmsJGlEPTBiPTCwMlAyPCEQvF2u	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEe3NEc,OjR7MEC3O\|A9N2F-
Rosetta2 (DE3)	MVvGeY5kfGmxbjDhd5NigQ>?				MmL2TY5pcWKrdHnvckBw\iCqdX3hckA3gGircz30ZYdo\WRiQWLUSFUhMDFyM{CgeI8hOTNzNzmg[ZhxemW\|c3XkJIlvKEW\|Y3jldolkcGmjIHPvcIkhWm:\|ZYT0ZVIhMESHMzmgZ4VtdHNidYPpcochVkGGKzDhd{B{fWK\|dILheIUh[nliZnz1c5Jme2OnbnPlJIF{e2G7LDDJR\|UxKD1iMD6wNlUh\|ryPLh?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEe3NEc,OjR7MEC3O\|A9N2F-
LoVo	NXj4V5ZpS3m2b4TvfIlkcXS7IHHzd4F6	NIrJeW8xNjRidV2=	M2DsOVUh\GG7cx?=		M4PqUXBwfGWwdHnheIlwdiCxZjD0[Y1wgm:ub33p[IUucW6mdXPl[EBkgXSxdH;4bYNqfHliaX6gbJVu[W5iTH;Wc{Bk\WyuczDhd5Nme3OnZDDhd{B1\W2xen;sc41q\GViR1m1NEBifCByLkSgeW0h[W[2ZYKgOUBl[Xm\|IHL5JGNmdGy2aYTldk1IdG9iYYPzZZktKEeLNUCgQUAxNjF2NDFOwG0v	Mk\GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK3NVcoRjJ4NkWyO\|E4RC:jPh?=
Capan1	NHS2NmlEgXSxdH;4bYNqfHliYYPzZZk>				NGT0TlBEgXSxdH;4bYNqfHliYXfhbY5{fCCEUlPBNk1l\W[rY3nlcpQhcHWvYX6gR4Fx[W5zIHPlcIx{NCCHQ{WwJF0hOC54MEmg{txONg>?	MmT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK3NVcoRjJ4NkWyO\|E4RC:jPh?=
MDA-MB-436	M3e1WmFvfGmlYX7j[ZIh[XO\|YYm=		Mni3PVYhcHK\|		MXTBcpRq[2GwY3XyJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQmLDRVEu\GWoaXPp[Y51KE2GQT3NRk01OzZiY3XscJMh[W[2ZYKgPVYhcHK\|IHL5JG1VXCCjc4PhfUwhS0N3MDC9JFMh\|ryPLh?=	M{\LeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{SyPFY5Lz5{NkO0Nlg3QDxxYU6=
OVCAR3	NWTQTFdjSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M4fsT\|I1KGi{cx?=		MWTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE:YQ1HSN{Bk\WyuczDh[pRmeiB{NDDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMz6zNUDPxE1w	NX7vd3hIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OVYyODZpPkK5OFU3OTB4PD;hQi=>
MRC5	NFLvXFBEgXSxdH;4bYNqfHliYYPzZZk>				M4LyXGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1TSzViY3XscJMtKEWFNUCgQUA5NjV\|IN88UU4>	M4exV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO\|E4Lz5{Nk[1NlcyPzxxYU6=
MCF7	NV7HSI9YSW62aXPhcoNmeiCjc4PhfS=>		MlTFPVYhcHK\|		MV;BcpRq[2GwY3XyJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB7NjDodpMh[nliTWTUJIF{e2G7LDDDR\|UxKD1iMUmuOFch\|ryPLh?=	NFzm[mQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO0Nlg3QCd-Mk[zOFI5Pjh:L3G+
A673	NWfxPZd1eUiWUzDhd5NigQ>?				MUDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	NX:5dIFoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	NHS1NXpyUFSVIHHzd4F6				NWPmZnlkeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSTZ5MzDj[Yxteyl?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	NEL5RXVyUFSVIHHzd4F6				M{HWZ5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpPDFiY3XscJM>	MljNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	NWH1WnY6eUiWUzDhd5NigQ>?				NWfRW2ZreUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
TC32	MorsdWhVWyCjc4PhfS=>				MVjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDUR\|MzKGOnbHzz	M{XvTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	PAR; PubMed: 27960087 Cancer Cell MCF-7 cells were pretreated ± Rucaparib (15 µM, 2 hr), then ± Rucaparib (15 µM) or two different doses of β-lap (2.0 or 5.0 µM) for 2 hr. Levels of PAR (PARP hyperactivation) formation were assessed with α-tubulin as loading controls. BRCA1; PubMed: 24085845 Proc Natl Acad Sci U S A MCF7 cells, MDA-MB-436 parental cells and resistant clones RR-1, RR-5, and RR-6 were treated with DMSO (−) or 1 µM rucaparib (+) for 24 h, and BRCA1 protein levels were assessed by using BRCA1 N- or C-terminal-specific antibodies by Western blot.	27960087 24085845
Growth inhibition assay	Cell viability; PubMed: 31119062 Adv Wound Care (New Rochelle) The effect of rucaparib on proliferation of keloid fibroblasts. (A) Keloid cell growth following treatment with rucaparib at various concentration (0, 2, 10, 20 μM) was evaluated by MTT assays. Data are expression as mean standard deviation of percent changes of triplicate optical densities. (B) Rucaparib (20 μM) significantly decreased proliferation of keloid fibroblasts. The combination of rucaparib (20 μM) and triamcinolone (50 μM) showed additive suppressive effect on keloid fibroblasts as compared with rucaparib single therapy. Data are expression as mean standard deviation of percent changes of triplicate optical densities. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.	31119062
Immunofluorescence	α-tubulin; PubMed: 30589644 J Clin Invest Representative immunofluorescence images of DMSO-, rucaparib- (Ruca-), and Ola-exposed A549-ERCC1(WT/WT) and A549-ERCC1(–/–) cells. Cells were exposed to 15 μM Ruca or 40 μM Ola during 72 hours. White arrows, CCFs; yellow arrows, micronuclei. Scale bar: 20 μm. PAR; PubMed: 27515310 BMC Cancer Cells were treated with 20 mM hydrogen peroxide (H2O2) in order to stimulate PARP-1 activity in the presence or absence of the PARP-1 inhibitors rucaparib and olaparib. Poly(ADP-ribose) (PAR) chain synthesis was detected using an anti-PAR monoclonal Alexa Fluor 488-conjugated antibody (green). The nucleus was visualised using the nuclear counterstain DAPI (blue). Representative images obtained from the analysis of anti-PAR staining of SK-N-BE(2c) cells are shown. γH2AX; PubMed: 23565244 PLoS One γH2AX foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells. 53BP1; PubMed: 23565244 PLoS One 53BP1 foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells.	30589644 27515310 23565244

体内試験

Rucaparib is not toxic but significantly enhances temozolomide-induced TGD in the DNA repair protein-competent D384Med xenografts. Pharmacokinetics studies also show that Rucaparib is detected in the brain tissue, which indicates that Rucaparib has potential in intra-cranial malignancy therapy. ^[4] Rucaparib significantly potentiates the cytotoxicity of topotecan and temozolomide in NB-1691, SH-SY-5Y, and SKNBE (2c) cells. Rucaparib enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts. ^[5]

お薦めの試験操作（参考用のみ）

キナーゼ試験：^[1]	- 合併 K_i Determination: Inhibition of human full-length recombinant PARP-1 by [³²P]NAD⁺ incorporation is measured. The [³²P]ADP-ribose incorporated into acid insoluble material is quantified using a PhosphorImager. K_i is calculated by nonlinear regression analysis.
細胞試験： ^[4]	- 合併細胞株： D425Med, D283Med and D384Med cells 濃度： 0.4 μM 反応時間： 3 or 5 days 実験の流れ： Medulloblastoma cell lines are seeded in 96-well plates at a density of 1 × 10³, 3 × 10³ and 3 × 10³, respectively. At 24 hours (D384Med) or 48 hours (D283Med and D425Med) after seeding, the cells are exposed to various concentrations of temozolomide in the presence or absence of 0.4 μM Rucaparib. After 3 days (D425Med and D384Med) or 5 days (D283Med) of culture, cell viability is evaluated by a XTT cell proliferation kit assay. Cell growth is expressed as a percentage in relation to DMSO or 0.4 μM Rucaparib-alone controls. The concentration of temozolomide, alone or in combination with Rucaparib that inhibited growth by 50% (GI50) is calculated. The potentiation factor 50 (PF50) is defined as the ratio of the GI50 of temozolomide in the presence of Rucaparib to the GI50 of temozolomide alone. (参考用のみ)
動物試験：^[4]	- 合併動物モデル： CD-1 nude mice bearing established D283Med xenografts 投薬量： 1 mg/kg 投与方法： One or four daily by i.p. (参考用のみ)

参考

- 合併

溶解度 (25°C)

体外	DMSO	84 mg/mL (199.35 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 2% DMSO+30% PEG 300+2% Tween 80+ddH2O 混合させたのち直ちに使用することを推奨します。	10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Rucaparib (AG-014699) phosphate SDFをダウンロードする

分子量	421.36
化学式	C₁₉H₁₈FN₃O.H₃PO₄
CAS No.	459868-92-9
Storage	3 years-20°C powder 2 years-80°C in solvent
別名	PF-01367338
Smiles	CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量

mg/kg

動物平均体重

投与体積（動物毎）

動物数

匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO+ % + % Tween 80+ % ddH₂O

計算リセット

計算結果:

投与溶媒濃度： mg/ml；

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL，注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。）

投与溶媒調製方法：μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04539327	Recruiting	Drug: Rucaparib	Epithelial Ovarian Cancer\|Fallopian Tube Cancer\|Primary Peritoneal Cancer	Grupo Español de Investigación en Cáncer de Ovario\|Clovis Oncology Inc.	July 29 2020	--
NCT04179396	Recruiting	Drug: Rucaparib\|Drug: Enzalutamide\|Drug: Abiraterone	Metastatic Castration Resistant Prostate Cancer	Clovis Oncology Inc.	December 5 2019	Phase 1
NCT04171700	Recruiting	Drug: Rucaparib	Solid Tumor	Clovis Oncology Inc.	November 21 2019	Phase 2
NCT03954366	Active not recruiting	Drug: Rucaparib\|Drug: Rosuvastatin\|Drug: Oral Contraceptives	Neoplasms	Clovis Oncology Inc.	May 8 2019	Phase 1
NCT03824704	Terminated	Drug: Rucaparib\|Drug: Nivolumab	Epithelial Ovarian Cancer\|Fallopian Tube Cancer\|Primary Peritoneal Carcinoma\|High Grade Serous Carcinoma\|Endometrioid Adenocarcinoma	Clovis Oncology Inc.\|Bristol-Myers Squibb\|Foundation Medicine	May 15 2019	Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

PARPシグナル伝達経路

PARP Inhibitors with Unique Features

Selective PARP Inhibitors

AG-14361 : PARP1-selective, K_i<5 nM.
Selective PARP Inhibitors

UPF 1069 : PARP2-selective, IC50=0.3 μM.
Most Potent PARP Inhibitor

MK-4827 (Niraparib) : PARP1, IC50=3.8 nM; PARP2, IC50=2.1 nM.
PARP Inhibitor in Clinical Trial

Iniparib (BSI-201) : Phase III for solid tumors.
Newest PARP Inhibitor

PJ34 HCl ^New : PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.

相関PARP製品

G007-LK

G007-LK is a potent and selective tankyrase inhibitor with IC50 of 46 nM and 25 nM for TNKS1/2, respectively.
NU1025

NU1025 (NSC 696807) is a potent PARP inhibitor with IC50 of 400 nM.
SCR7

SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).
Olaparib (AZD2281)

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Olaparib induces significant autophagy that is associated with mitophagy in cells with BRCA mutations.

Features:A potent PARP inhibitor (currently in late stage clinical trials).
Veliparib (ABT-888)

Veliparib (ABT-888, NSC 737664) is a potent inhibitor of PARP1 and PARP2 with K_i of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Veliparib increases autophagy and apoptosis. Phase 3.

Features:Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Talazoparib (BMN 673)

Talazoparib (BMN 673, LT-673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

Features:Most potent and selective PARPi reported thus far.
Iniparib (BSI-201)

Iniparib (BSI-201, NSC-746045, IND-71677) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). Phase 3.

研究分野別

製品類型

Rucaparib (AG-014699) phosphate

文献中Selleckの製品使用例(86)

製品安全説明書

PARP阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Rucaparib (AG-014699) phosphate SDFをダウンロードする

投与溶媒組成計算器(クリア溶液)

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2020-01-06)

技術サポート

PARPシグナル伝達経路

PARP Inhibitors with Unique Features

相関PARP製品